Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin- etoposide hybrid chemotherapy in small cell lung cancer

T. Ohnoshi, S. Hiraki, H. Ueoka, Katsuyuki Kiura, H. Kamei, T. Horiguchi, T. Kodani, T. Maeda, Masahiro Tabata, T. Shibayama, Y. Segawa, K. Miyatake, N. Takigawa, I. Kimura

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background. Small cell lung cancer (SCLC) is highly sensitive to chemotherapy. Despite the introduction of intensive combination chemotherapy, long-term disease-free survivors are still rare. The emergence of drug- resistant tumor cells during chemotherapy is presumed to be the major cause of poor outcome. Methods. A pilot Phase II study of hybrid chemotherapy for patients with SCLC was conducted between October 1986 and March 1988. Dose and schedule for each drug in the regimen were as follows: cyclophosphamide, 700 mg/m 2 intravenously (IV), day 1; doxorubicin, 30 mg/m 2 IV, day 1; vincristine, 1.4 mg/m 2 IV, day 1; cisplatin, 60 mg/m 2 IV, day 8; and etoposide, 100 mg/m 2 IV, days 8 and 9. Courses were repeated every 4 weeks for up to six cycles. Patients with limited disease (LD) received chest irradiation of 5000 cGy when a maximal response was achieved. Only patients with LD who achieved a complete response (CR) received prophylactic cranial irradiation of 3000 cGy. Results. Thirty-six patients were enrolled and fully evaluated for tumor response and toxicity. All 20 patients with LD responded to the regimen, and 14 (70%) of those achieved a CR. Of 16 patients with extensive disease (ED), 7 CR and 7 partial responses were noted, indicating an overall response rate of 88%. The median survival time was 23.6 months for patients with LD and 12.6 months for those with ED. Myelosuppression was the major toxicity, but it was generally well tolerated. Conclusions. These results indicate that the hybrid regimen is a highly active one for the treatment of patients with SCLC and warrants additional clinical trials.

Original languageEnglish
Pages (from-to)1597-1601
Number of pages5
JournalCancer
Volume72
Issue number5
Publication statusPublished - 1993

Fingerprint

Small Cell Lung Carcinoma
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Cisplatin
Drug Therapy
Cranial Irradiation
Combination Drug Therapy
Pharmaceutical Preparations
Survivors
Neoplasms
Appointments and Schedules
Thorax
Clinical Trials
Survival

Keywords

  • chemotherapy
  • drug resistance
  • hybrid regimen
  • small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ohnoshi, T., Hiraki, S., Ueoka, H., Kiura, K., Kamei, H., Horiguchi, T., ... Kimura, I. (1993). Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin- etoposide hybrid chemotherapy in small cell lung cancer. Cancer, 72(5), 1597-1601.

Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin- etoposide hybrid chemotherapy in small cell lung cancer. / Ohnoshi, T.; Hiraki, S.; Ueoka, H.; Kiura, Katsuyuki; Kamei, H.; Horiguchi, T.; Kodani, T.; Maeda, T.; Tabata, Masahiro; Shibayama, T.; Segawa, Y.; Miyatake, K.; Takigawa, N.; Kimura, I.

In: Cancer, Vol. 72, No. 5, 1993, p. 1597-1601.

Research output: Contribution to journalArticle

Ohnoshi, T, Hiraki, S, Ueoka, H, Kiura, K, Kamei, H, Horiguchi, T, Kodani, T, Maeda, T, Tabata, M, Shibayama, T, Segawa, Y, Miyatake, K, Takigawa, N & Kimura, I 1993, 'Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin- etoposide hybrid chemotherapy in small cell lung cancer', Cancer, vol. 72, no. 5, pp. 1597-1601.
Ohnoshi, T. ; Hiraki, S. ; Ueoka, H. ; Kiura, Katsuyuki ; Kamei, H. ; Horiguchi, T. ; Kodani, T. ; Maeda, T. ; Tabata, Masahiro ; Shibayama, T. ; Segawa, Y. ; Miyatake, K. ; Takigawa, N. ; Kimura, I. / Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin- etoposide hybrid chemotherapy in small cell lung cancer. In: Cancer. 1993 ; Vol. 72, No. 5. pp. 1597-1601.
@article{0a6e25351e304df8990b94b7d21e019e,
title = "Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin- etoposide hybrid chemotherapy in small cell lung cancer",
abstract = "Background. Small cell lung cancer (SCLC) is highly sensitive to chemotherapy. Despite the introduction of intensive combination chemotherapy, long-term disease-free survivors are still rare. The emergence of drug- resistant tumor cells during chemotherapy is presumed to be the major cause of poor outcome. Methods. A pilot Phase II study of hybrid chemotherapy for patients with SCLC was conducted between October 1986 and March 1988. Dose and schedule for each drug in the regimen were as follows: cyclophosphamide, 700 mg/m 2 intravenously (IV), day 1; doxorubicin, 30 mg/m 2 IV, day 1; vincristine, 1.4 mg/m 2 IV, day 1; cisplatin, 60 mg/m 2 IV, day 8; and etoposide, 100 mg/m 2 IV, days 8 and 9. Courses were repeated every 4 weeks for up to six cycles. Patients with limited disease (LD) received chest irradiation of 5000 cGy when a maximal response was achieved. Only patients with LD who achieved a complete response (CR) received prophylactic cranial irradiation of 3000 cGy. Results. Thirty-six patients were enrolled and fully evaluated for tumor response and toxicity. All 20 patients with LD responded to the regimen, and 14 (70{\%}) of those achieved a CR. Of 16 patients with extensive disease (ED), 7 CR and 7 partial responses were noted, indicating an overall response rate of 88{\%}. The median survival time was 23.6 months for patients with LD and 12.6 months for those with ED. Myelosuppression was the major toxicity, but it was generally well tolerated. Conclusions. These results indicate that the hybrid regimen is a highly active one for the treatment of patients with SCLC and warrants additional clinical trials.",
keywords = "chemotherapy, drug resistance, hybrid regimen, small cell lung cancer",
author = "T. Ohnoshi and S. Hiraki and H. Ueoka and Katsuyuki Kiura and H. Kamei and T. Horiguchi and T. Kodani and T. Maeda and Masahiro Tabata and T. Shibayama and Y. Segawa and K. Miyatake and N. Takigawa and I. Kimura",
year = "1993",
language = "English",
volume = "72",
pages = "1597--1601",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin- etoposide hybrid chemotherapy in small cell lung cancer

AU - Ohnoshi, T.

AU - Hiraki, S.

AU - Ueoka, H.

AU - Kiura, Katsuyuki

AU - Kamei, H.

AU - Horiguchi, T.

AU - Kodani, T.

AU - Maeda, T.

AU - Tabata, Masahiro

AU - Shibayama, T.

AU - Segawa, Y.

AU - Miyatake, K.

AU - Takigawa, N.

AU - Kimura, I.

PY - 1993

Y1 - 1993

N2 - Background. Small cell lung cancer (SCLC) is highly sensitive to chemotherapy. Despite the introduction of intensive combination chemotherapy, long-term disease-free survivors are still rare. The emergence of drug- resistant tumor cells during chemotherapy is presumed to be the major cause of poor outcome. Methods. A pilot Phase II study of hybrid chemotherapy for patients with SCLC was conducted between October 1986 and March 1988. Dose and schedule for each drug in the regimen were as follows: cyclophosphamide, 700 mg/m 2 intravenously (IV), day 1; doxorubicin, 30 mg/m 2 IV, day 1; vincristine, 1.4 mg/m 2 IV, day 1; cisplatin, 60 mg/m 2 IV, day 8; and etoposide, 100 mg/m 2 IV, days 8 and 9. Courses were repeated every 4 weeks for up to six cycles. Patients with limited disease (LD) received chest irradiation of 5000 cGy when a maximal response was achieved. Only patients with LD who achieved a complete response (CR) received prophylactic cranial irradiation of 3000 cGy. Results. Thirty-six patients were enrolled and fully evaluated for tumor response and toxicity. All 20 patients with LD responded to the regimen, and 14 (70%) of those achieved a CR. Of 16 patients with extensive disease (ED), 7 CR and 7 partial responses were noted, indicating an overall response rate of 88%. The median survival time was 23.6 months for patients with LD and 12.6 months for those with ED. Myelosuppression was the major toxicity, but it was generally well tolerated. Conclusions. These results indicate that the hybrid regimen is a highly active one for the treatment of patients with SCLC and warrants additional clinical trials.

AB - Background. Small cell lung cancer (SCLC) is highly sensitive to chemotherapy. Despite the introduction of intensive combination chemotherapy, long-term disease-free survivors are still rare. The emergence of drug- resistant tumor cells during chemotherapy is presumed to be the major cause of poor outcome. Methods. A pilot Phase II study of hybrid chemotherapy for patients with SCLC was conducted between October 1986 and March 1988. Dose and schedule for each drug in the regimen were as follows: cyclophosphamide, 700 mg/m 2 intravenously (IV), day 1; doxorubicin, 30 mg/m 2 IV, day 1; vincristine, 1.4 mg/m 2 IV, day 1; cisplatin, 60 mg/m 2 IV, day 8; and etoposide, 100 mg/m 2 IV, days 8 and 9. Courses were repeated every 4 weeks for up to six cycles. Patients with limited disease (LD) received chest irradiation of 5000 cGy when a maximal response was achieved. Only patients with LD who achieved a complete response (CR) received prophylactic cranial irradiation of 3000 cGy. Results. Thirty-six patients were enrolled and fully evaluated for tumor response and toxicity. All 20 patients with LD responded to the regimen, and 14 (70%) of those achieved a CR. Of 16 patients with extensive disease (ED), 7 CR and 7 partial responses were noted, indicating an overall response rate of 88%. The median survival time was 23.6 months for patients with LD and 12.6 months for those with ED. Myelosuppression was the major toxicity, but it was generally well tolerated. Conclusions. These results indicate that the hybrid regimen is a highly active one for the treatment of patients with SCLC and warrants additional clinical trials.

KW - chemotherapy

KW - drug resistance

KW - hybrid regimen

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0027172017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027172017&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 1597

EP - 1601

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -